ANTABUSE TREATMENT OF NICKEL DERMATITIS - CHELATION - NEW PRINCIPLE IN THE TREATMENT OF NICKEL DERMATITIS

Eleven nickel‐hypersensitive patients with chronic, dyshidrotic hand eczema aggravated by oral challenge with 0.6–2.5 mg nickel were treated with 100 mg tetraethylthiuramdisulfide (Antabuse®) two to four times daily for 4–10 weeks. Nine of the patients experienced a flare of the dermatitis shortly after initiation of the treatment. During the course of treatment the dermatitis of seven patients, cleared, improvement was seen in two patients, and in two the dermatitis remained unchanged. Flare was seen in six patients when the treatment was discontinued. Seven patients experienced side effects such as fatigue, headache and dizziness. The treatment of four patients was discontinued due to side effects. During the treatment high levels of nickel were found in the serum and urine. Copyright © 1979, Wiley Blackwell. All rights reserved